EUVIMEDEUVIMED entdecken
Crossref

A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting

Yanying Li, Yue Gao iD, Xianghao Xiao, Aiyu Li, Lili Xia, Ruiqi Ji, Jianjun Zhang, Xiangyang Shi iD, Mingwu Shen iD

Biomacromolecules · 09.11.2026 · 27 (11) · 7614-7624

DOI: 10.1021/acs.biomac.6c01657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 20.10.2026. Verfasst von Yanying Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Bio…. Hauptthemen laut MEDLINE: Nanovaccines, Dendrimers, Erythrocytes, Cancer Vaccines. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient antigen delivery to antigen-presenting cells remains a critical challenge in cancer nanovaccine development. In this study, we develop a dendrimer-based nanovaccine (DenV) for efficient tumor treatment and prevention via a red blood cell (RBC) hitchhiking strategy. Utilizing phenylboronic acid-grafted dendrimers, model antigen ovalbumin (OVA) and immune adjuvant CpG oligodeoxynucleotide (CpG ODN) can be efficiently co-loaded to get DenV with a relatively simple fabrication process. Upon further RBC anchoring, DenV@RBC demonstrates a distinct application feature from DenV with a desired delivery profile to lymphoid organs. In vivo antitumor results in a mouse subcutaneous melanoma model show that both DenV and DenV@RBC achieve excellent antitumor effects following systemic administration, where the therapeutic efficacy of DenV@RBC is slightly superior to that of DenV. Meanwhile, DenV and DenV@RBC allow excellent tumor-preventive effects, regardless of local or systematic administration routes. It is also found that DenV is more robust upon local injection, while DenV@RBC yields better tumor prevention performance when administered systemically via the bloodstream. Our study offers a dendrimer-based strategy with interaction to natural RBCs for the development of highly efficient nanovaccines and holds substantial application potential in the field of cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanovaccinesDendrimersErythrocytesCancer VaccinesMelanoma, ExperimentalAnimalsMiceOligodeoxyribonucleotidesBoronic AcidsOvalbuminFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

antigen-presentationdendrimershitchhikingnanovaccinered blood cells

Substanzen

NanovaccinesDendrimersOligodeoxyribonucleotidesCancer VaccinesBoronic AcidsOvalbuminCPG-oligonucleotidebenzeneboronic acid

Autor:innen und Institutionen

  • State Key Laboratory of Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai2…
  • Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200336, China.

ORCID-Profile: Yue Gao, Xiangyang Shi, Mingwu Shen

Förderung

  • National Natural Science Foundation of China (NSFC)
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Li, Y., Gao, Y., Xiao, X., Li, A., Xia, L., Ji, R., Zhang, J., Shi, X., & Shen, M. (2026). A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting. Biomacromolecules, 27(11), 7614-7624. https://doi.org/10.1021/acs.biomac.6c01657

Vancouver

Li Y, Gao Y, Xiao X, Li A, Xia L, Ji R, et al. A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting. Biomacromolecules. 2026;27(11):7614-7624. doi:10.1021/acs.biomac.6c01657

BibTeX
@article{Li2026,
  author = {Li, Yanying and Gao, Yue and Xiao, Xianghao and Li, Aiyu and Xia, Lili and Ji, Ruiqi and Zhang, Jianjun and Shi, Xiangyang and Shen, Mingwu},
  title = {A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting},
  journal = {Biomacromolecules},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {7614--7624},
  doi = {10.1021/acs.biomac.6c01657}
}
Kostenlos starten →